EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prolonged inhibition of intratumoral mast cells enhances efficacy of low‐dose antiangiogenic therapy

Nikolaus Berenbrok, Maria Elena Vargas-Delgado, Antonia Beitzen-Heineke, Claudia Schmidt, Victoria Gensch, Sonja Loges, Isabel Ben-Batalla iD

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Nikolaus Berenbrok und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), German Center for Lung Research (DZL), Heidelberg, Germany. Hauptthemen laut MEDLINE: Mast Cells, Imatinib Mesylate, Angiogenesis Inhibitors, Neovascularization, Pathologic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Universität Hamburg, H2020 European Research Council (ERC), Deutsche Forschungsgemeinschaft (DFG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low‐dose antiangiogenic therapies have demonstrated the ability to enhance normalization of tumor vessels, consequently improving hypoxia levels, drug delivery, and promoting anticancer immune responses. Mast cells have been identified as contributors to resistance against antiangiogenic therapy and facilitators of abnormal neoangiogenesis. In this study, we demonstrate that by simultaneously targeting intratumoral mast cells with Imatinib and administering low‐dose anti‐VEGFR2 therapy, antitumor efficacy can be enhanced in preclinical models. Thus, combinatory treatment overcomes therapy resistance, while concurrently promoting tumor vessel normalization. Notably, histomorphometric analysis of tumor sections revealed that vessel perfusion could be improved through mast cell inhibition and, despite a significantly reduced microvessel density, the combination treatment did not result in elevated tumor hypoxia levels compared to anti‐VEGFR2 therapy alone. Short‐term Imatinib application effectively increased antitumor efficacy, and by prolonging the application of Imatinib tumor vessel normalization was additionally improved. The combination of mast cell depletion and antiangiogenic treatments has not been investigated in detail and promises to help overcoming therapy resistance. Further studies will be required to explore their impact on other treatment approaches, and subsequently to validate these findings in a clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mast CellsImatinib MesylateAngiogenesis InhibitorsNeovascularization, PathologicAnimalsMiceHumansCell Line, TumorVascular Endothelial Growth Factor Receptor-2FemaleXenograft Model Antitumor Assays

Stichwörter der Autor:innen

antiangiogenic therapyhypoxiamast cell inhibitiontherapy resistance

Substanzen

Imatinib MesylateAngiogenesis InhibitorsVascular Endothelial Growth Factor Receptor-2

Autor:innen und Institutionen

  • Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), German Center for Lung Research (DZL), Heidelberg, Germany.
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Department of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Department for Oncology, Hematology and Bone Marrow Transplantation with the Section Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center, Hamburg, Germany.
  • Light Microscopy Facility (W210), German Cancer Research Center (DKFZ), Heidelberg, Germany.

ORCID-Profile: Isabel Ben-Batalla

Förderung

  • Universität Hamburg
  • H2020 European Research Council (ERC)
  • Deutsche Forschungsgemeinschaft (DFG)
  • Hector Stiftung II
  • European Research Council

Zitieren

APA

Berenbrok, N., Vargas-Delgado, M. E., Beitzen-Heineke, A., Schmidt, C., Gensch, V., Loges, S., & Ben-Batalla, I. (2025). Prolonged inhibition of intratumoral mast cells enhances efficacy of low‐dose antiangiogenic therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.35132

Vancouver

Berenbrok N, Vargas-Delgado ME, Beitzen-Heineke A, Schmidt C, Gensch V, Loges S, et al. Prolonged inhibition of intratumoral mast cells enhances efficacy of low‐dose antiangiogenic therapy. International Journal of Cancer. 2025. doi:10.1002/ijc.35132

BibTeX
@article{Berenbrok2025,
  author = {Berenbrok, Nikolaus and Vargas-Delgado, Maria Elena and Beitzen-Heineke, Antonia and Schmidt, Claudia and Gensch, Victoria and Loges, Sonja and Ben-Batalla, Isabel},
  title = {Prolonged inhibition of intratumoral mast cells enhances efficacy of low‐dose antiangiogenic therapy},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35132}
}
Kostenlos starten →